Biotech & Pharma Company Valuation
Value a drug developer program by program, each at its own chance of approval, from the pitch deck, the company's pipeline page or a US ticker.
29 valuation methods · 43 industries · Results in under 10 minutes
In short
A biotech or pharma company is valued program by program on risk-adjusted net present value: each program's sales are weighted by its chance of approval from its phase, the company's running costs come off and its cash goes on. The phase, the peak sales, the launch timing and the partners' share move the value most.
Who this is for
Founders and finance leads of clinical-stage drug developers raising a round, partnering a program or preparing a sale, and the investors and business development teams who value one from a deck, a pipeline page or a US-listed company's filings. A drug company that already has sales of its own is covered too.
How is a biotech or pharma company valued?
VA values a drug developer on risk-adjusted net present value (rNPV), one program at a time. Each program's sales are forecast from its launch year up to its peak and down again after its exclusivity ends, within a forecast window of ten to fifteen years, with no value counted after it, and its sales and trial costs are weighted by its chance of approval: the share of programs in its phase that went on to be approved, from the BIO, Informa and QLS study of clinical development success. A partnered program counts only the company's share. The company's running costs and tax are charged across the whole pipeline, then cash is added and debt subtracted, and the company's cash and other assets less its liabilities set a floor under the value. For a company without sales, the rNPV carries the whole value, and comparable companies and precedent transactions are shown beside it as checks only; once the company sells, they join the blend. This tool is informational only. Output is driven by your inputs and does not constitute a formal appraisal or certified valuation.
What drives the value of a biotech or pharma company?
- The phase each program has reached, which sets its chance of approval
- Peak sales for each program: the patients it can treat and the price per patient
- How soon each program launches, and how long its exclusivity lasts after that
- The share of each program the company keeps after its partners take theirs
- Cash, which adds to the value, against the running costs charged across the pipeline
- More than one program, so a single trial result does not decide the whole value
What lowers the value of a biotech or pharma company?
- A lead program in an early phase, where most programs fail
- A pivotal trial that runs late and pushes the launch back
- A partner that keeps most of a program's sales
- Running costs that outweigh what the pipeline is expected to earn
- Exclusivity that ends soon after launch
See how it works
One minute: a clinical-stage drug developer valued from its pitch deck, program by program.
The guide opens on Arcade in a new tab: “Biotech: value a drug pipeline from the pitch deck”.
Value your biotech or pharma company in under 10 minutes
- 1.Upload your financial statements, or type the figures in.
- 2.Confirm the add-backs and the industry details the model asks for.
- 3.Get a valuation range, the methods behind it and a PDF memorandum.
Not ready yet? Try the calculator or see a sample report.
Which numbers matter most?
Chance of approval
The share of programs in a phase that went on to be approved, through the phases still ahead. VA weights each program's sales and trial costs by it, and a figure the company states can replace it.
Peak sales
A program's sales in its best year. VA takes the figure the deck prints, with its page, or builds one from the patients the drug can treat, the price per patient and the share it can win, and, in a valuation in US dollars, flags a built peak above the ceiling for the program's stage.
Launch year
When a program reaches the market. A program with no stated year takes the usual time from its phase, and each year of delay lowers what its sales are worth today.
The company's share
The part of a program's sales and costs the company keeps under a partnership or license. A partnered program is valued on that share alone.
Running costs and runway
Research and administrative spending from the statements or filings, charged against the pipeline, and the months the cash lasts at the current burn.
Value per fully diluted share
The equity divided by the fully diluted share count, from the cap table or, for a US-listed company, from its filings. Where preferred shares take their preferences first, VA shows what a common share is worth after them.
What do you need to value a biotech or pharma company?
- Profit and loss statements and balance sheets, ideally for the last three years
- Figures for the current year to date
- A list of add-backs: the owner's pay and perks, and any one-off costs
- Loan and lease balances
- The pitch deck or company overview, with each program's phase, indication and partner
- The address of the company's website or pipeline page, or its ticker if it is listed in the US
- For each partnered program, the share of its sales and costs the company keeps under the partnership or license
- The cap table, with every share class, the options and any convertible instruments
Example scenarios
The lead program's next result
Bear and bull move each program's chance of approval, the lead program's most, and the discount rate, and the bear pushes launches later; an approved drug moves on its sales and the end of its exclusivity instead. The spread shows how far the value moves when trials go worse or better than the averages for their phase.
A launch that slips
A pivotal trial runs longer than planned. The delayed launch case moves every launch not yet approved later, with the chances of approval unchanged, and is shown as a fourth case beside the bear, base and bull.
A deck that leaves gaps
The deck names each program and its phase but says nothing about its market. For the leading programs, VA searches the drug's price and the patients it would treat, shows where each figure came from, marks its own estimates as such and uses nothing until you approve it.
Further reading
WACC Explained: Why Your Discount Rate Can Make or Break a Valuation
WACC is one of the most misunderstood terms in business valuation. Here's what it is, why it matters, and how it directly affects what your business is worth.
Why Your Business Valuation Is a Range, Not a Number
A single valuation number is a red flag. Here's why serious buyers, investors, and advisors always think in ranges - and how to interpret yours.
DCF Analysis Explained for Private Companies
A clear, practical guide to discounted cash flow analysis for private companies. Learn the five key steps, how to estimate WACC without public market data, terminal value approaches, and common pitfalls to avoid.
Frequently asked questions
How is a biotech company valued?
On risk-adjusted net present value, program by program: each program's sales and trial costs are weighted by its chance of approval and discounted to today, the company's running costs and tax come off and its cash goes on. Comparable companies and precedent transactions join the blend once the company has sales of its own.
Where do the chances of approval come from?
From the BIO, Informa and QLS study of clinical development success: the share of programs that passed each phase, multiplied through the phases a program still has ahead. Preclinical programs take an estimate below the first clinical phase, and you can replace any program's figure with the company's own.
What can I start from?
The pitch deck as a PDF, the address of the company's website or its pipeline page, or the ticker of a US-listed company, whose SEC filings VA reads. Each program's phase, indication, partner and peak sales are read as printed, with the page they came from, and nothing is used until you approve it.
What if the deck gives no peak sales?
For the leading programs, VA searches the drug's price and the number of patients it would treat, shows the sources and builds the peak from them. Where nothing is found, VA's own estimate is marked as such, or the figure is left for you to enter. You can change any figure before it is used.
Does the cap table change the value?
No. The cap table splits the value between the share classes, it never moves it. VA reads each class and shows what each class takes and what a common share is worth after the preferences.
What if the pipeline is worth less than the cash?
Then the value is held at the asset floor, the company's cash and other assets less its liabilities, until the pipeline's value rises above it, and the valuation page says so. The floor anchors the downside and is never an upside case.
What does a listed company's share price add?
For a US-listed company, a check, never an input. VA shows the market capitalization, with the date and source of the share count and the price, beside its own value and says how far apart the two are.
Can I test my own assumptions?
Yes. You can edit each program on the valuation page and run the valuation again. For a company without sales, the value drivers view also shows the value against the chances of approval, the peak sales, the launch timing and the discount rate.
What does the report include?
A PDF memorandum with the pipeline, each program's value and the range. With Pro or Team you also get a PowerPoint deck and an Excel model, whose sensitivity tab shows the value at other chances of approval and peak sales.
Is this a certified appraisal?
No. This is an informational estimate. A bank loan, a partner buyout or an estate matter may require a certified business appraisal, which this does not replace.
Terms used on this page
- Risk-adjusted net present value (rNPV)
- A discounted cash flow for one drug program in which its sales and costs count only as far as they are likely to happen. Summed across the programs, less the company's running costs, it values a pipeline that has no profits yet.
- Chance of approval
- The share of drug programs that passed each phase, multiplied through the phases a program still has ahead. A later-stage program has a higher chance, so more of its sales count in the value.
- Discount rate
- The yearly return a buyer requires for the risk of owning the business. A higher rate lowers what future cash is worth today.
- Asset floor
- The value of the company's own assets, such as equipment and inventory, net of what it owes. VA does not let a valuation fall below it.
- Comparable companies
- A method that values a business at the multiples of earnings or revenue at which similar companies are valued.
- Precedent transactions
- A method that values a business at the multiples paid in past sales of similar companies.
- Cash runway
- How many months the cash on hand lasts at the company's burn, the cash it spends each month beyond what comes in.
- Fully diluted shares
- The shares issued plus those that options, warrants and convertible instruments such as SAFEs would add. Value per fully diluted share is the equity divided by that count.
As featured in
Value your biotech or pharma company
Get a valuation range with the methods behind it and a PDF memorandum in under 10 minutes.
Related industries
Biotech
Value a biotech or life sciences company using risk-adjusted NPV, pipeline analysis, and precedent transaction comps.
Healthcare Devices
Value a medical device company on its products, each forecast at its own odds of reaching the market, with the cap table, the next round and the runway it buys.
Medical Labs
Value a clinical or diagnostic lab on its test volume and the net reimbursement it collects per test, with fee-schedule pressure and operating leverage read as buyers do.
CRO Services
Value a clinical research organization or CRO using backlog multiples, EBITDA, and revenue per FTE benchmarks.
Last reviewed October 12, 2026 against VA's valuation models.